CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 208 enrolled
Drug / intervention
AcrySof® IQ ReSTOR® +3.0 D Multifocal IOL +2 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01290068
NCT01290068N/ACompleted
CompareCT.gov

Visual Outcomes After Bilateral Surgical Cataract Phacoemulsification: AcrySof® ReSTOR IOL Implantation Compared to Monofocal IOL Implantation

Alcon Research·interventional·Posted Feb 4, 2011·Updated Jul 2, 2018

In Brief

A clinical study evaluating AcrySof® IQ ReSTOR® +3.0 D Multifocal IOL, AcrySof® IQ ReSTOR® +3.0 D Multifocal Toric IOL, and 1 other intervention for Cataract. Completed, enrolled 208 participants.

Detailed Summary

The purpose of this study is to assess and compare visual outcomes of the AcrySof® IQ ReSTOR® +3.0 D intraocular lens (IOL) to a commercially available monofocal IOL in cataract patients.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCataract
Countries--
Collaborators--

Timeline

N/ACompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedFeb 4, 2011
Enrollment StartApr 1, 2011
Primary CompletionOct 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 15.4 years ago

Interventions

AcrySof® IQ ReSTOR® +3.0 D Multifocal IOLdevice

Multifocal IOL with extended secondary focal point implanted for long-term use over the lifetime of the cataract patient

AcrySof® IQ ReSTOR® +3.0 D Multifocal Toric IOLdevice

Multifocal IOL with extended secondary focal point and astigmatism correction implanted for long-term use over the lifetime of the cataract patient

Monofocal IOLdevice

Monofocal IOL implanted for long-term use over the lifetime of the cataract patient